Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials

2012/04/04 by R Leong, Rupert W. Leong, Md L T Vieira +9 · 27 citations
Medicine · Economics, Econometrics and Finance · Pharmacology, Toxicology and Pharmaceutics · #Pharmaceutical studies and practices #Pharmaceutical Economics and Policy #Pharmacogenetics and Drug Metabolism

paper · doi:10.1038/clpt.2012.19

Abstract

Physiologically based pharmacokinetic (PBPK) approaches that incorporate the developmental physiology and ontogeny of cytochrome P450 (CYP) enzymes may have value in the design of pediatric trials. Four recent submissions to the US Food and Drug Administration (FDA) incorporated different PBPK applications to pediatric drug development.Further testing of PBPK models for three drugs showed that these models generally under predicted drug clearance. PBPK modeling may have potential for improving pediatric trials through the learn-and-confirm approaches utilized in current regulatory submissions.

Cited by

• Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children
• State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
• Optimizing drug development of anti-cancer drugs in children using modelling and simulation. [europepmc]
• Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. [europepmc]
• A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. [europepmc]
• Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. [europepmc]
• Pharmacokinetic studies in infants using minimal-risk study designs. [europepmc]
• Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. [europepmc]
• Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. [europepmc]
• Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. [europepmc]
• Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation. [europepmc]
• Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. [europepmc]
• Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data. [europepmc]
• In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. [europepmc]
• Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. [europepmc]
• Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives. [europepmc]
• Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making. [europepmc]
• A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse. [europepmc]
• A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate. [europepmc]
• Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. [europepmc]
• Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making. [europepmc]
• Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters. [europepmc]
• Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences. [europepmc]
• Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. [europepmc]
• Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. [europepmc]
• Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. [europepmc]
• Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. [europepmc]

Related

• Physiologically Based Pharmacokinetic (PBPK) Modeling in Children
• Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children
• Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies
• Evaluation of physiologically based pharmacokinetic models for use in risk assessment
• Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study